<DOC>
	<DOC>NCT01634087</DOC>
	<brief_summary>This is a study of INCB039110 in patients with chronic plaque psoriasis. This study will evaluate safety and efficacy parameters of INCB039110.</brief_summary>
	<brief_title>A Study of Escalating Doses of INCB039110 Administered Orally in Patients With Plaque Psoriasis</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Subjects with chronic plaque psoriasis aged 18 to 75 who have had insufficient response to topical agents, and who meet the psoriasis assessment expectations as defined in the study protocol Females who are pregnant or breastfeeding Men and women who cannot comply with requirements to avoid fathering a child or becoming pregnant, respectively Subjects treated with leflunomide or other biological therapies to treat psoriasis and all JAKSTAT inhibitors within 12 weeks prior to first dose of study drug</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>